{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Deep venous thrombus/Pulmonary Embolism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Pneumonia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Upper respiratory infections"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Sinusitis/acute otitis media"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Epiglottic appendagitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Cellulitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Clostridium difficile colitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Vaginitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Peripheral neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dermal leukocytic vasculitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Secondary cancer Acute Myeloid Leukemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Re-occurrence of skin cancer"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"Patients receive clarithromycin orally (PO) twice a day and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.\n\nNOTE: \\*After one year of treatment, dexamethasone is tapered for an additional 4 weeks.\n\nClarithromycin: Given PO\n\nDexamethasone: Given PO\n\nLenalidomide: Given PO","id":"OG000","title":"Treatment (Clarithromycin, Dexamethasone, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"First year of therapy","title":"Episodes of Grade 3-4 Non Infectious, Non-dermatological or Non-neurological Toxicities, Episodes of Any Infections, Grade 3-4 Dermatological or Episodes of Grade 2-3 Peripheral Neuropathy Common Terminology Criteria for Adverse Events Version 3","type":"PRIMARY","unitOfMeasure":"episodes"}